Biosimilar Interleukins Global Market Report 2024

The biosimilar interleukins market size has grown exponentially in recent years. It will grow from $3.9 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 39.0%. The growth observed in the historical period can be attributed to several factors. These include the escalating prevalence of autoimmune diseases requiring targeted treatments with biosimilar interleukins, a growing awareness regarding the efficacy and benefits of these treatments among healthcare providers and patients, increasing governmental support for the development and utilization of biosimilars, expansion in the biosimilar market offering more options, and a rising demand from patients seeking accessible and effective treatment options through biosimilar medications. These factors collectively contributed to the growth and adoption of biosimilar interleukins during this period.

The biosimilar interleukins market size is expected to see exponentially grown in the next few years. It will grow to $20.79 billion in 2028 at a compound annual growth rate (CAGR) of 40.0%. Anticipated growth in the forecast period is expected due to several key factors. These include the expansion of the patient population seeking treatment with biosimilar interleukins, improved accessibility to healthcare services facilitating their use, a growing demand for personalized medicine tailoring treatments to individual needs, and an increased preference for minimally invasive medical procedures.

The anticipated rise in autoimmune diseases like psoriasis and rheumatoid arthritis is poised to propel growth within the interleukin biosimilars market in the upcoming forecast period. These conditions involve immune cells struggling to differentiate between healthy and potentially harmful antibodies. Biologic drugs, including anti-interleukin antibodies, have demonstrated significant clinical benefits by regulating cells and influencing their proliferation, activation, and migration. A report from Johns Hopkins University in 2021 estimated that autoimmune diseases impacted around 3% of the United States population, affecting roughly 10 million individuals. This escalating prevalence of autoimmune diseases is expected to fuel the demand for biosimilar interleukins and drive market growth.

The increasing prevalence of arthritis is forecasted to drive the growth of the biosimilar interleukins market. Arthritis, characterized by joint discomfort or inflammation, encompasses conditions affecting one or multiple joints. Biosimilars containing interleukins are pivotal in managing various inflammatory and autoimmune conditions, including rheumatoid arthritis (RA), psoriatic arthritis, and others. As per the Centers for Disease Control and Prevention's projections in October 2021, it is anticipated that by 2040, approximately 78.4 million adults aged 18 and older, roughly 25.9% of the projected adult population, will receive a physician's diagnosis of arthritis, marking an increase from 63 million in 2020. Consequently, the escalating prevalence of arthritis is set to propel the growth of the biosimilar interleukins market. Key players in the biosimilar interleukins market are introducing innovative products like Tofidence (tocilizumab-bavi) to bolster their profitability in the market. Tofidence, a monoclonal antibody targeting and binding to interleukin-6 receptors, serves in treating various inflammatory autoimmune disorders. In September 2023, Biogen, a US-based biotechnology company, received FDA approval for Tofidence (tocilizumab-bavi) as the initial biosimilar to Genentech's Actemra (tocilizumab). Administered via intravenous infusion, Tofidence has gained approval for treating severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis, marking a strategic move to enhance their market presence and profitability.

Equillium, a biotech company headquartered in the United States, finalized the acquisition of Bioniz Therapeutics, Inc. In February 2022 for a substantial sum of $329 million. This acquisition significantly expands Equillium's array of innovative immunomodulatory drug candidates by providing access to three therapeutics and additional assets in the discovery phase. Bioniz Therapeutics Inc., also based in the United States, is a biotechnology company specializing in this field. This strategic acquisition is poised to strengthen Equillium's portfolio and accelerate its efforts in developing cutting-edge treatments in the realm of immunomodulation.

Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter PLC, Bio-Thera Solutions Ltd., Sorrento Therapeutics, Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Biogen Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline PLC, Eli Lilly and Company, AstraZeneca PLC, Bristol-Myers Squibb Company, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. De C.V., Biosidus S.A., LG Life Sciences, Mylan N.V.

North America was the largest region in the biosimilar interleukins market in 2023. The regions covered in the biosimilar interleukins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The biosimilar interleukins market consists of sales of mabPharm, gedeonrichter, and bio-thera solutions. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Various types of biosimilar interleukins include IL-17, IL-23, IL-1, IL-5, IL-6, among others. For instance, Interleukin 17 belongs to the pro-inflammatory cystine knot cytokine family and is produced by a specific subset of T helper cells, known as T helper 17 cells, in response to IL-23 stimulation. These biosimilar interleukins find diverse applications in treating conditions such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), and other immune-related disorders. They are made available through various distribution channels, including hospital pharmacies, online pharmacies, retail pharmacies, clinics, as well as research institutes, catering to different healthcare settings and patient needs.

The biosimilar interleukins market research report is one of a series of new reports provides biosimilar interleukins market statistics, including biosimilar interleukins industry global market size, regional shares, competitors with a biosimilar interleukins market share, detailed biosimilar interleukins market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar interleukins industry. The biosimilar interleukins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.